Combined Nivolumab and Ipilimumab in Melanoma Metastatic to the
Por um escritor misterioso
Descrição
First-line nivolumab plus ipilimumab versus chemotherapy in patients with unresectable malignant pleural mesothelioma: 3-year outcomes from CheckMate 743 - Annals of Oncology
VisualAbstract: Nivolumab plus ipilimumab may be less effective in females with melanoma compared to males
PDF] Combined Nivolumab and Ipilimumab or Monotherapy in Previously Untreated Melanoma
Combined nivolumab and ipilimumab versus ipilimumab alone in patients with advanced melanoma: 2-year overall survival outcomes in a multicentre, randomised, controlled, phase 2 trial - The Lancet Oncology
A phase 1/2 trial of an immune-modulatory vaccine against IDO/PD-L1 in combination with nivolumab in metastatic melanoma
Metastatic Melanoma Therapies OPDIVO® (nivolumab) + YERVOY® (ipilimumab)
Immunotherapy First for BRAF Melanoma Edges Out Targeted Combination
OPDIVO® (nivolumab) + YERVOY® (ipilimumab) Efficacy in Metastatic Melanoma
Long-term outcomes of patients with active melanoma brain metastases treated with combination nivolumab plus ipilimumab (CheckMate 204): final results of an open-label, multicentre, phase 2 study - The Lancet Oncology
Ipilimumab alone or in combination with nivolumab in patients with advanced melanoma who have progressed or relapsed on PD-1 blockade: clinical outcomes and translational biomarker analyses
Cancers, Free Full-Text
Combination nivolumab and ipilimumab or nivolumab alone in melanoma brain metastases: a multicentre randomised phase 2 study - The Lancet Oncology
Ipilimumab plus nivolumab for patients with metastatic uveal melanoma: a multicenter, retrospective study
PDF) Combined Nivolumab and Ipilimumab in Melanoma Metastatic to the Brain
Five-Year Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma
de
por adulto (o preço varia de acordo com o tamanho do grupo)
